Re: Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer

Eur Urol. 2024 Jul;86(1):74-75. doi: 10.1016/j.eururo.2024.02.021. Epub 2024 Mar 26.

Authors

Igor Duquesne¹, Alexandre de la Taille²

Affiliations

¹ Department of Urology, Henri Mondor Hospital, University of Paris Est Créteil, Créteil, France. Electronic address: [email protected].
² Department of Urology, Henri Mondor Hospital, University of Paris Est Créteil, Créteil, France.

PMID: 38538425
DOI: 10.1016/j.eururo.2024.02.021

No abstract available

Publication types

Letter

MeSH terms

Adjuvants, Immunologic / adverse effects
Adjuvants, Immunologic / therapeutic use
BCG Vaccine* / adverse effects
BCG Vaccine* / therapeutic use
Humans
Neoplasm Invasiveness
Non-Muscle Invasive Bladder Neoplasms
Pyrazoles* / therapeutic use
Quinoxalines / therapeutic use
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / pathology

Substances

BCG Vaccine
erdafitinib
Pyrazoles
Quinoxalines
Adjuvants, Immunologic